PROFOUND MEDICAL CORP (PROF)

Company Profile

Profound Medical Corp. engages in developing, manufacturing, and marketing of therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 131 full-time employees. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Company Info

PROFOUND MEDICAL CORP

2400 Skymark Ave Unit 6

Mississauga ONTARIO L4W 5K5

P: 16474761350

CEO: Arun Menawat

Employees: 131

Website: https://profoundmedical.com/